Amylin as a future obesity treatment introducing cagrilintideNote significant GI adverse effects cf. placebo but no apparent plateauing of weight loss after 26 weeks Umbrella Labs Cagrilintide Peptide Research Use Only Program Expands Laboratory Access For High Rigor Amylin Receptor, Calcitonin Receptor, And Neuroendocrine Signaling Bench Science Cagrilintide 10mg Long Acting Amylin Analog Midwest Peptide Development of Cagrilintide, a Long Acting Amylin Analogue Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity Diabetes Therapy Springer Nature Link